Alexandria Real Estate Equities, Inc. Announces Foundational Milestone in Mission-Critical Partnership with the Foundation for the National Institutes of Health to Advance Precision Medicine for Depression
Alexandria Real Estate Equities announced the completion of the design phase for the MAP-D initiative, a precision medicine partnership with the Foundation for the National Institutes of Health aimed at redefining the diagnosis and treatment of major depressive disorder. The research effort is expected to exceed $70 million, launching with a $22 million, three-year pilot phase to identify biological signatures and enable personalized treatment approaches. As the founding strategic partner, Alexandria provided the initial catalytic funding and was recognized by the FNIH in 2025 with the Charles A.
Key figures
- Map d pilot funding
- $22 million
- Map d total funding
- $70 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.